123 results on '"Grosse, Scott D."'
Search Results
2. Ganciclovir and Valganciclovir Use Among Infants With Congenital Cytomegalovirus: Data From a Multicenter Electronic Health Record Dataset in the United States.
- Author
-
Leung, Jessica, Grosse, Scott D, Yockey, Bryan, and Lanzieri, Tatiana M
- Subjects
- *
GANCICLOVIR , *RESEARCH , *NEONATAL intensive care , *CYTOMEGALOVIRUS diseases , *MORTALITY , *NEUTROPENIA , *NEONATAL intensive care units , *TREATMENT duration , *RACE , *HEALTH outcome assessment , *VALGANCICLOVIR , *DESCRIPTIVE statistics , *ELECTRONIC health records , *ETHNIC groups , *CHILDREN - Abstract
Among 342 US infants with congenital cytomegalovirus treated with antivirals, 114 (33%) received ganciclovir (with or without valganciclovir) and 228 (67%) received valganciclovir only, for a median of 8 and 171 days, starting at a median of 15 and 45 days of life, respectively, with neutropenia diagnosed in 25% and 17%. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Direct costs of adhering to selected Duchenne muscular dystrophy Care Considerations: Estimates from a midwestern state.
- Author
-
Conway, Kristin M., Grosse, Scott D., Ouyang, Lijing, Street, Natalie, and Romitti, Paul A.
- Abstract
Introduction/Aims: The multidisciplinary Duchenne muscular dystrophy (DMD) Care Considerations were developed to standardize care and improve outcomes. We provide cumulative cost estimates for selected key preventive (ie, excluding new molecular therapies and acute care) elements of the care considerations in eight domains (neuromuscular, rehabilitation, respiratory, cardiac, orthopedic, gastrointestinal, endocrine, psychosocial management) independent of completeness of uptake or provision of nonpreventive care. Methods: We used de‐identified insurance claims data from a large midwestern commercial health insurer during 2018. We used Current Procedural Terminology and national drug codes to extract unit costs for clinical encounters representing key preventive elements of the DMD Care Considerations. We projected per‐patient cumulative costs from ages 5 to 25 years for these elements by multiplying a schedule of recommended frequencies of preventive services by unit costs in 2018 US dollars. Results: Assuming a diagnosis at age 5 years, independent ambulation until age 11, and survival until age 25, we estimated 670 billable clinical events. The 20‐year per‐patient cumulative cost was $174 701 with prednisone ($2.3 million with deflazacort) and an expected total of $12 643 ($29 194) for out‐of‐pocket expenses associated with those events and medications. Discussion: Standardized monitoring of disease progression and treatments may reduce overall costs of illness. Costs associated with these services would be needed to quantify potential savings. Our approach demonstrates a method to estimate costs associated with implementation of preventive care schedules. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Healthcare Costs of Pediatric Autism Spectrum Disorder in the United States, 2003–2015.
- Author
-
Zuvekas, Samuel H., Grosse, Scott D., Lavelle, Tara A., Maenner, Matthew J., Dietz, Patricia, and Ji, Xu
- Subjects
- *
MEDICAL care costs , *CONFIDENCE intervals , *PEDIATRICS , *AUTISM in children , *COST analysis , *DESCRIPTIVE statistics , *DATA analysis software - Abstract
Published healthcare cost estimates for children with autism spectrum disorder (ASD) vary widely. One possible contributor is different methods of case ascertainment. In this study, ASD case status was determined using two sources of parent reports among 45,944 children ages 3–17 years in the Medical Expenditure Panel Survey (MEPS) linked to the National Health Interview Survey (NHIS) Sample Child Core questionnaire. In a two-part regression model, the incremental annual per-child cost of ASD relative to no ASD diagnosis was $3930 (2018 US dollars) using ASD case status from the NHIS Child Core and $5621 using current-year ASD case status from MEPS. Both estimates are lower than some published estimates but still represent substantial costs to the US healthcare system. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Identification of congenital CMV cases in administrative databases and implications for monitoring prevalence, healthcare utilization, and costs.
- Author
-
Grosse, Scott D., Leung, Jessica, and Lanzieri, Tatiana M.
- Subjects
- *
CYTOMEGALOVIRUS diseases , *HEALTH insurance claims , *MEDICAL care costs , *COST estimates , *HOSPITAL admission & discharge , *DATABASES - Abstract
To critically review researchers' use of diagnosis codes to identify congenital cytomegalovirus (cCMV) infection or disease in healthcare administrative databases. Understanding the limitations of cCMV ascertainment in those databases can inform cCMV surveillance and health services research. We identified published studies that used diagnosis codes for cCMV or CMV in hospital discharge or health insurance claims and encounters records for infants to assess prevalence, use of services, or healthcare costs. We reviewed estimates of prevalence and of charges, costs, or expenditures associated with cCMV diagnosis codes. Five studies assessed hospitalizations with cCMV diagnosis codes recorded in hospital discharge databases, from the United States (n = 3), Australia (n = 1), and the United Kingdom (n = 1). Six other studies analyzed claims or encounters data from the United States (n = 5) or Japan (n = 1) to identify infants with cCMV codes. Prevalence estimates of recognized cCMV ranged from 0.6 to 3.8 per 10,000 infants. Economic analyses reported a wide range of per-hospitalization or per-infant cost estimates, which lacked standardization or comparability. The administrative prevalence of cCMV cases reported in published analyses of administrative data from North America, Western Europe, Japan, and Australia (0.6–3.8 per 10,000 infants) is an order of magnitude lower than the estimates of the true birth prevalence of 3–7 per 1,000 newborns based on universal newborn screening pilot studies conducted in the same regions. Nonetheless, in the absence of systematic surveillance for cCMV, administrative data might be useful for assessing trends in testing and clinical diagnosis. To the extent that cCMV cases recorded in administrative databases are not representative of the full spectrum of cCMV infection or disease, per-child cost estimates generated from those data may not be generalizable. On the other hand, claims data may be useful for estimating patterns of healthcare use and expenditures associated with combinations of diagnoses for cCMV and known complications of cCMV. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Progress in expanding newborn screening in the United States.
- Author
-
Grosse, Scott D., Cuthbert, Carla, Gaffney, Marcus, Gaviglio, Amy, Hinton, Cynthia F., Kellar-Guenther, Yvonne, Kemper, Alex R., McKasson, Sarah, Ojodu, Jelili, Riley, Catharine, Singh, Sikha, Sontag, Marci K., and Shapira, Stuart K.
- Subjects
- *
NEWBORN screening - Published
- 2023
- Full Text
- View/download PDF
7. Quantifying Family Spillover Effects in Economic Evaluations: Measurement and Valuation of Informal Care Time.
- Author
-
Grosse, Scott D., Pike, Jamison, Soelaeman, Rieza, and Tilford, J. Mick
- Subjects
- *
CONTINGENT valuation , *OPPORTUNITY costs , *CONJOINT analysis , *VALUATION , *TIME management - Abstract
Spillover effects on the welfare of family members may refer to caregiver health effects, informal care time costs, or both. This review focuses on methods that have been used to measure and value informal care time and makes suggestions for their appropriate use in cost-of-illness and cost-effectiveness analyses. It highlights the importance of methods to value informal care time that are independent of caregiver health effects in order to minimize double counting of spillover effects. Although the concept of including caregiver time costs in economic evaluations is not new, relatively few societal perspective cost-effectiveness analyses have included informal care, with the exception of dementia. This is due in part to challenges in measuring and valuing time costs. Analysts can collect information on time spent in informal care or can assess its impact in displacing other time use, notably time in paid employment. A key challenge is to ensure appropriate comparison groups that do not require informal care to be able to correctly estimate attributable informal care time or foregone market work. To value informal care time, analysts can use estimates of hourly earnings in either opportunity cost or replacement cost approaches. Researchers have used widely varying estimates of hourly earnings. Alternatively, stated-preference methods (i.e. contingent valuation, conjoint analysis) can be used to value the effect of informal care on utility, but this can entail double counting with health effects. Lack of consensus and standardization of methods makes it difficult to compare estimates of informal care costs. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Actions in Support of Newborn Screening for Critical Congenital Heart Disease - United States, 2011-2018.
- Author
-
Glidewell, Jill, Grosse, Scott D., Riehle-Colarusso, Tiffany, Pinto, Nelangi, Hudson, Jeff, Daskalov, Rachel, Gaviglio, Amy, Darby, Erin, Singh, Sikha, and Sontag, Marci
- Subjects
- *
CONGENITAL heart disease diagnosis , *NEWBORN screening , *HEALTH policy - Abstract
In 2011, the U.S. Department of Health and Human Services added critical congenital heart disease (CCHD), which occurs in two of every 1,000 births, to the list of conditions recommended to states for universal newborn screening (1). Without early detection, infants with CCHD are at risk for substantial morbidity and death in the first weeks and months of life (2). Based on 2007-2013 data, deaths from CCHD and other cardiac causes in infants aged <6 months significantly declined in infants born in eight states after they had fully implemented mandated newborn CCHD screening policies by June 2013 (3). CDC collaborated with the American Academy of Pediatrics (AAP) and the Association of Public Health Laboratories' Newborn Screening Technical Assistance and Evaluation Program (NewSTEPs) to update a 2015 report (4) on states' actions toward adopting and implementing policies supporting CCHD newborn screening. In 2018, all 50 states and the District of Columbia (DC) had implemented CCHD screening policies, and, with one exception, all states mandated that screening be done (California mandates that screening be offered). However, not all states had data systems in place for tracking all screening results and outcomes. Ongoing evaluation activities, which rely on screening data, could help identify program improvement opportunities and monitor the impact of early identification of CCHD. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. Precision Medicine In Action: The Impact Of Ivacaftor On Cystic Fibrosis-Related Hospitalizations.
- Author
-
Feng, Lisa B., Grosse, Scott D., Green, Ridgely Fisk, Fink, Aliza K., and Sawicki, Gregory S.
- Subjects
- *
HOSPITAL care , *HOSPITALS , *CYSTIC fibrosis , *PROBABILITY theory , *HEALTH insurance reimbursement , *TREATMENT effectiveness , *PRE-tests & post-tests , *INDIVIDUALIZED medicine , *DESCRIPTIVE statistics , *ECONOMICS - Abstract
Cystic fibrosis is a life-threatening genetic disease that causes severe damage to the lungs. Ivacaftor, the first drug that targeted the underlying defect of the disease caused by specific mutations, is a sterling example of the potential of precision medicine. Clinical trial and registry studies showed that ivacaftor improved outcomes and reduced hospitalizations. Our study used US administrative claims data to assess the real-world effectiveness of ivacaftor. Comparing twelve-month rates before and after starting the use of ivacaftor among people who initiated therapy during 2012-2015, we found that overall and cystic fibrosis-related inpatient admissions fell by 55 percent and 81 percent, respectively. There was a comparable reduction in inpatient spending. Ivacaftor appears to be effective for multiple mutations that cause the disease, as suggested by the fact that during the study period, ivacaftor's use was extended to nine additional mutations in 2014. Examination of evidence from clinical trial, clinical care, and administrative data sources is important for understanding the real-world effectiveness of precision medicines such as ivacaftor. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
10. Adjusting Health Expenditures for Inflation: A Review of Measures for Health Services Research in the United States.
- Author
-
Dunn, Abe, Grosse, Scott D., and Zuvekas, Samuel H.
- Subjects
- *
MEDICAL care costs , *GROSS domestic product , *MEDICAL care , *PUBLIC health , *MANAGEMENT , *ECONOMIC statistics , *MEDICAL care cost statistics , *COST effectiveness , *ECONOMIC aspects of diseases , *MEDICAL care research , *STATISTICAL models - Abstract
Objective: To provide guidance on selecting the most appropriate price index for adjusting health expenditures or costs for inflation.Data Sources: Major price index series produced by federal statistical agencies.Study Design: We compare the key characteristics of each index and develop suggestions on specific indexes to use in many common situations and general guidance in others.Data Collection/extraction Methods: Price series and methodological documentation were downloaded from federal websites and supplemented with literature scans.Principal Findings: The gross domestic product implicit price deflator or the overall Personal Consumption Expenditures (PCE) index is preferable to the Consumer Price Index (CPI-U) to adjust for general inflation, in most cases. The Personal Health Care (PHC) index or the PCE health-by-function index is generally preferred to adjust total medical expenditures for inflation. The CPI medical care index is preferred for the adjustment of consumer out-of-pocket expenditures for inflation. A new, experimental disease-specific Medical Care Expenditure Index is now available to adjust payments for disease treatment episodes.Conclusions: There is no single gold standard for adjusting health expenditures for inflation. Our discussion of best practices can help researchers select the index best suited to their study. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
11. Association of US State Implementation of Newborn Screening Policies for Critical Congenital Heart Disease With Early Infant Cardiac Deaths.
- Author
-
Abouk, Rahi, Grosse, Scott D., Ailes, Elizabeth C., and Oster, Matthew E.
- Subjects
- *
CONGENITAL heart disease in children , *MEDICAL screening , *HEALTH policy , *NEONATAL death , *DIAGNOSIS , *CONGENITAL heart disease diagnosis , *CONGENITAL heart disease , *NEWBORN screening , *INFANT mortality , *MANAGEMENT , *MORTALITY , *STATE governments , *VITAL statistics , *MEDICAL laws ,NEWBORN infant health - Abstract
Importance: In 2011, critical congenital heart disease was added to the US Recommended Uniform Screening Panel for newborns, but whether state implementation of screening policies has been associated with infant death rates is unknown.Objective: To assess whether there was an association between implementation of state newborn screening policies for critical congenital heart disease and infant death rates.Design, Setting, and Participants: Observational study with group-level analyses. A difference-in-differences analysis was conducted using the National Center for Health Statistics' period linked birth/infant death data set files for 2007-2013 for 26 546 503 US births through June 30, 2013, aggregated by month and state of birth.Exposures: State policies were classified as mandatory or nonmandatory (including voluntary policies and mandates that were not yet implemented). As of June 1, 2013, 8 states had implemented mandatory screening policies, 5 states had voluntary screening policies, and 9 states had adopted but not yet implemented mandates.Main Outcomes and Measures: Numbers of early infant deaths (between 24 hours and 6 months of age) coded for critical congenital heart disease or other/unspecified congenital cardiac causes for each state-month birth cohort.Results: Between 2007 and 2013, there were 2734 deaths due to critical congenital heart disease and 3967 deaths due to other/unspecified causes. Critical congenital heart disease death rates in states with mandatory screening policies were 8.0 (95% CI, 5.4-10.6) per 100 000 births (n = 37) in 2007 and 6.4 (95% CI, 2.9-9.9) per 100 000 births (n = 13) in 2013 (for births by the end of July); for other/unspecified cardiac causes, death rates were 11.7 (95% CI, 8.6-14.8) per 100 000 births in 2007 (n = 54) and 10.3 (95% CI, 5.9-14.8) per 100 000 births (n = 21) in 2013. Early infant deaths from critical congenital heart disease through December 31, 2013, decreased by 33.4% (95% CI, 10.6%-50.3%), with an absolute decline of 3.9 (95% CI, 3.6-4.1) deaths per 100 000 births after states implemented mandatory screening compared with prior periods and states without screening policies. Early infant deaths from other/unspecified cardiac causes declined by 21.4% (95% CI, 6.9%-33.7%), with an absolute decline of 3.5 (95% CI, 3.2-3.8) deaths per 100 000 births. No significant decrease was associated with nonmandatory screening policies.Conclusions and Relevance: Statewide implementation of mandatory policies for newborn screening for critical congenital heart disease was associated with a significant decrease in infant cardiac deaths between 2007 and 2013 compared with states without these policies. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
12. Treated Prevalence of Attention-Deficit/Hyperactivity Disorder Increased from 2009 to 2015 Among School-Aged Children and Adolescents in the United States.
- Author
-
Nyarko, Kwame A., Grosse, Scott D., Danielson, Melissa L., Holbrook, Joseph R., Visser, Susanna N., and Shapira, Stuart K.
- Subjects
- *
TREATMENT of attention-deficit hyperactivity disorder , *EMPLOYER-sponsored health insurance , *MEDICAID , *DISEASE prevalence , *YOUTH with attention-deficit hyperactivity disorder , *CHILDREN with attention-deficit hyperactivity disorder , *EMPLOYER-sponsored health insurance statistics , *ATTENTION-deficit hyperactivity disorder , *DATABASES , *LONGITUDINAL method , *RESEARCH funding ,MEDICAID statistics - Abstract
Objectives: The purpose of this brief is to describe changes in the treated prevalence of medically managed attention-deficit/hyperactivity disorder (ADHD) among insured school-aged children and adolescents in the United States from 2009 to 2015. We examine the differences between those with employer-sponsored insurance (ESI) and with Medicaid insurance.Methods: We utilized two large longitudinal administrative datasets containing medical and drug claims data on individuals with ESI and Medicaid insurance from Truven Health MarketScan® Administrative Claims Databases. Treated prevalence was measured as the percentage of school-aged children and adolescents enrolled in a calendar year who met the criteria for medically managed ADHD in the same calendar year. Subjects were eligible for inclusion if they were aged 6-17 years and were continuously enrolled during a calendar year.Results: The annual prevalence of treated ADHD among school-aged children and adolescents with ESI increased from 4.5% in 2009 to 6.7% in 2015. Among those with Medicaid it increased from 11.3% in 2009 to 13.3% in 2012, and fell after 2012, remaining steady from 2013 through 2015.Conclusion: Treated prevalence of ADHD increased continuously over time among school-aged children and adolescents with ESI, but declined slightly after 2012 among those in the Medicaid sample. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
13. The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience.
- Author
-
GROSSE, SCOTT D., THOMPSON, JOHN D., DING, YAO, and GLASS, MICHAEL
- Subjects
- *
CYSTIC fibrosis diagnosis , *INFANT mortality , *HEALTH policy , *POLICY sciences , *COST effectiveness , *ECONOMIC aspects of diseases , *NEWBORN screening , *OXIDOREDUCTASES , *QUALITY of life , *CHILDREN , *ECONOMICS , *PREVENTION - Abstract
Context Economic evaluations can inform policy decisions on the expansion of newborn screening panels. This article documents the use of cost-benefit models in Washington State as part of the rule-making process that resulted in the implementation of screening for medium-chain acyl-CoA dehydrogenase (MCAD) deficiency and 4 other metabolic disorders in 2004, cystic fibrosis (CF) in 2006, 15 other metabolic disorders in 2008, and severe combined immune deficiency (SCID) in 2014. Methods We reviewed Washington State Department of Health internal reports and spreadsheet models of expected net societal benefit of adding disorders to the state newborn screening panel. We summarize the assumptions and findings for 2 models (MCAD and CF) and discuss them in relation to findings in the peer-reviewed literature. Findings The MCAD model projected a benefit-cost ratio of 3.4 to 1 based on assumptions of a 20.0 percentage point reduction in infant mortality and a 13.9 percentage point reduction in serious developmental disability. The CF model projected a benefit-cost ratio of 4.0-5.4 to 1 for a discount rate of 3%-4% and a plausible range of 1-2 percentage point reductions in deaths up to age 10 years. Conclusions The Washington State cost-benefit models of newborn screening were broadly consistent with peer-reviewed literature, and their findings of net benefit appear to be robust to uncertainty in parameters. Public health newborn screening programs can develop their own capacity to project expected costs and benefits of expansion of newborn screening panels, although it would be most efficient if this capacity were shared among programs. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
14. Spending by California’s Department of Developmental Services for Persons with Autism across Demographic and Expenditure Categories.
- Author
-
Leigh, J. Paul, Grosse, Scott D., Cassady, Diana, Melnikow, Joy, and Hertz-Picciotto, Irva
- Subjects
- *
AUTISM spectrum disorders , *MEDICAL care costs , *ETHNICITY , *DAY care aides , *DISEASE prevalence - Abstract
Background: Few autism spectrum disorder (ASD) studies have estimated non-medical costs for treatment or addressed possible differences in provision of services across gender, race-ethnic, age or demographic or expenditure categories, especially among adults. Methods: The California Department of Developmental Services (CDDS) provides services to residents with developmental disabilities. CDDS provided aggregate data on primarily non-medical spending for fiscal year 2012–2013 for persons with ASD with or without intellectual disability (ID) (main sample, n = 42,274), and two sub-samples: ASD only (n = 30,164), and ASD+ID (n = 12,110). Demographic variables included sex, age and race-ethnicity. Spending categories included Employment Support, Community Care Facilities, Day Care, Transportation, and in-home and out-of-home Respite. Results: Per-person spending for males and females were approximately the same: $10,488 and $10,791 for males and females for ages 3–17 and $26,491 and $26,627 for ages 18+. Among race/ethnicity categories, the ranking from highest to lowest among ages 3–17 was white non-Hispanics ($11,480), Asian non-Hispanics ($11,036), “Others” ($11,031), Hispanics ($9,571), and African-American non-Hispanics ($9,482). For ages 18+, the ranking was whites ($31,008), African-Americans ($26,831), “Others” ($25,395), Asians ($22,993), and Hispanics ($18,083). The ASD+ID sub-sample exerted disproportionate influence on findings from the main sample for persons 18+. Combining all ages, the top two expenditure categories for per-person spending were Community Care Facilities ($43,867) and Day Care ($11,244). For most adult age groups, the percentage of recipients participating were highest for Day Care (44.9% - 62.4%) and Transportation (38.6% - 50.9%). Per-person spending for Day Care, Transportation, and Employment Support was relatively low for children but relatively high for adults. Conclusion: White non-Hispanics received the highest per-person spending and Hispanics among the least. Amounts within spending categories varied considerably across age groups. Our estimates may be useful as baseline measures for stakeholders preparing for increasing ASD prevalence, especially among adults. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
15. The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs.
- Author
-
Grosse, Scott D., Nelson, Richard E., Nyarko, Kwame A., Richardson, Lisa C., and Raskob, Gary E.
- Subjects
- *
THROMBOEMBOLISM , *MEDICAL care costs , *ETIOLOGY of diseases , *ANTICOAGULANTS , *DRUG side effects - Abstract
Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is an important cause of preventable mortality and morbidity. In this study, we summarize estimates of per-patient and aggregate medical costs or expenditures attributable to incident VTE in the United States. Per-patient estimates of incremental costs can be calculated as the difference in costs between patients with and without an event after controlling for differences in underlying health status. We identified estimates of the incremental per-patient costs of acute VTEs and VTE-related complications, including recurrent VTE, post-thrombotic syndrome, chronic thromboembolic pulmonary hypertension, and anticoagulation-related adverse drug events. Based on the studies identified, treatment of an acute VTE on average appears to be associated with incremental direct medical costs of $12,000 to $15,000 (2014 US dollars) among first-year survivors, controlling for risk factors. Subsequent complications are conservatively estimated to increase cumulative costs to $18,000-23,000 per incident case. Annual incident VTE events conservatively cost the US healthcare system $7-10 billion each year for 375,000 to 425,000 newly diagnosed, medically treated incident VTE cases. Future studies should track long-term costs for cohorts of people with incident VTE, control for comorbid conditions that have been shown to be associated with VTE, and estimate incremental medical costs for people with VTE who do not survive. The costs associated with treating VTE can be used to assess the potential economic benefit and cost-savings from prevention efforts, although costs will vary among different patient groups. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
16. CDC Grand Rounds: Newborn Screening for Hearing Loss and Critical Congenital Heart Disease.
- Author
-
Grosse, Scott D., Riehle-Colarusso, Tiffany, Gaffney, Marcus, Mason, Craig A., Shapira, Stuart K., Sontag, Marci K., Van Naarden Braun, Kim, Iskander, John, and Braun, Kim Van Naarden
- Subjects
- *
NEWBORN screening , *DIAGNOSIS of deafness , *CONGENITAL heart disease diagnosis , *EARLY medical intervention , *POINT-of-care testing - Abstract
Newborn screening is a public health program that benefits 4 million U.S. infants every year by enabling early detection of serious conditions, thus affording the opportunity for timely intervention to optimize outcomes (1). States and other U.S. jurisdictions decide whether and how to regulate newborn screening practices. Most newborn screening is done through laboratory analyses of dried bloodspot specimens collected from newborns. Point-of-care newborn screening is typically performed before discharge from the birthing facility. The Recommended Uniform Screening Panel includes two point-of-care conditions for newborn screening: hearing loss and critical congenital heart disease (CCHD). The objectives of point-of-care screening for these two conditions are early identification and intervention to improve neurodevelopment, most notably language and related skills among infants with permanent hearing loss, and to prevent death or severe disability resulting from delayed diagnosis of CCHD. Universal screening for hearing loss using otoacoustic emissions or automated auditory brainstem response was endorsed by the Joint Committee on Infant Hearing in 2000 and 2007* and was incorporated in the first Recommended Uniform Screening Panel in 2005. Screening for CCHD using pulse oximetry was recommended by the Advisory Committee on Heritable Disorders in Newborns and Children in 2010 based on an evidence review† and was added to the Recommended Uniform Screening Panel in 2011.§. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
17. Using multiple sources of data for surveillance of postoperative venous thromboembolism among surgical patients treated in Department of Veterans Affairs hospitals, 2005-2010.
- Author
-
Nelson, Richard E., Grosse, Scott D., Waitzman, Norman J., Junji Lin, DuVall, Scott L., Patterson, Olga, James Tsai, and Reyes, Nimia
- Subjects
- *
POSTOPERATIVE period , *ANTICOAGULANTS , *OPERATIVE surgery , *THROMBOEMBOLISM , *DIAGNOSIS , *PATIENTS - Abstract
Background There are limitations to using administrative data to identify postoperative venous thromboembolism (VTE). We used a novel approach to quantify postoperative VTE events among Department of Veterans Affairs (VA) surgical patients during 2005-2010. Methods We used VA administrative data to exclude patients with VTE during 12 months prior to surgery. We identified probable postoperative VTE events within 30 and 90 days post-surgery in three settings: 1) pre-discharge inpatient, using a VTE diagnosis code and a pharmacy record for anticoagulation; 2) post-discharge inpatient, using a VTE diagnosis code followed by a pharmacy record for anticoagulation within 7 days; and 3) outpatient, using a VTE diagnosis code and either anticoagulation or a therapeutic procedure code with natural language processing (NLP) to confirm acute VTE in clinical notes. Results Among 468,515 surgeries without prior VTE, probable VTEs were documented within 30 and 90 days in 3,931 (0.8%) and 5,904 (1.3%), respectively. Of probable VTEs within 30 or 90 days post-surgery, 47.8% and 62.9%, respectively, were diagnosed post-discharge. Among post-discharge VTE diagnoses, 86% resulted in a VA hospital readmission. Fewer than 25% of outpatient records with both VTE diagnoses and anticoagulation prescriptions were confirmed by NLP as acute VTE events. Conclusion More than half of postoperative VTE events were diagnosed post-discharge; analyses of surgical discharge records are inadequate to identify postoperative VTE. The NLP results demonstrate that the combination of VTE diagnoses and anticoagulation prescriptions in outpatient administrative records cannot be used to validly identify postoperative VTE events. Highlights • ~ 40% of possible pre-discharge VTEs based on ICD-9 codes classified as not probable. • NLP was used on outpatient clinical notes to assess VTEs with no VA readmission. • Just 21-23% of possible outpatient VTE diagnosed classified as probable based on NLP. • Probable VTEs < 90 days of surgery in 1.3% of VA patients, majority after discharge. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
18. Screening for Congenital Cytomegalovirus After Newborn Hearing Screening: What Comes Next?
- Author
-
Grosse, Scott D., Dollard, Sheila C., and Kimberlin, David W.
- Subjects
- *
DIAGNOSIS of deafness , *AUDIOMETRY , *CYTOMEGALOVIRUS diseases , *DEAFNESS , *EARLY intervention (Education) , *EARLY diagnosis , *DISEASE complications , *CHILDREN - Abstract
The article discusses a study by M. Diener and colleagues, published within the issue on the experience with targeted screening for congenital cytomegalovirus (cCMV) in Utah among infants who do not pass newborn hearing screening (NBHS). Topics include the benefits of targeted screening, the potential of universal screening of newborns for cCMV to increase detection of symptomatic infections, and controversial aspect of targeted screening in Utah.
- Published
- 2017
- Full Text
- View/download PDF
19. A comparison of family financial and employment impacts of fragile X syndrome, autism spectrum disorders, and intellectual disability.
- Author
-
Ouyang, Lijing, Grosse, Scott D., Riley, Catharine, Bolen, Julie, Bishop, Ellen, Raspa, Melissa, and Bailey, Donald B.
- Subjects
- *
EMPLOYMENT , *COMPARATIVE studies , *ECONOMIC impact , *FRAGILE X syndrome , *AUTISM spectrum disorders , *MENTAL illness - Abstract
Highlights: [•] A sample of children with FXS were matched with children with autism spectrum disorder (ASD) only, or intellectual disabilities (ID) only, or ASD and ID. [•] Higher percentage of caregivers of FXS reported negative financial and employment impacts than caregivers of ASD or ID only. [•] Caregivers of FXS reported similar financial and employment impacts as caregivers of both ASD and ID. [•] Co-occurring anxiety or seizures, limits in overall ability, and more irritability were associated with negative caregiver impacts. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
20. Criteria for fairly allocating scarce health-care resources to genetic tests: which matter most?
- Author
-
Rogowski, Wolf H, Grosse, Scott D, Schmidtke, Jörg, and Marckmann, Georg
- Subjects
- *
MEDICAL care financing , *GENETIC testing , *HEALTH care management industry , *INDUSTRIAL hygiene , *SOCIAL services , *INFORMATION resources - Abstract
The use of genetic tests is expanding rapidly. Given limited health-care budgets throughout Europe and few national coverage decisions specifically for genetic tests, decisions about allocating scarce resources to genetic tests are frequently ad hoc and left to lower-level decision makers. This study assesses substantive ethical and economic criteria to prioritize genetic services in a reasonable and fair manner. Principles for allocating health-care resources can be classified into four categories: need-based allocation; maximizing total benefits; treating people equally; and promoting and rewarding social usefulness. In the face of scarcity, the degree of an individual's need for medical intervention is an important criterion. Also, different economic concepts of efficiency are of relevance in the theory and practice of prioritizing genetic tests. Equity concerns are most likely to be relevant in terms of avoiding undesirable inequities, which may also set boundaries to the use of efficiency as a prioritization criterion. The aim of promoting and rewarding social usefulness is unlikely to be relevant to the question of what priority a genetic test should have in clinical practice. Further work is needed to select an appropriate set of criteria; operationalize them; and assign weights before some kind of standardized priority information can be added to information sources for genetic services. Besides the substantive criteria, formal considerations like those pointed out in the framework of accountability for reasonableness need to be considered in decision making. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
21. A Public Health Economic Assessment of Hospitals' Cost to Screen Newborns for Critical Congenital Heart Disease.
- Author
-
Peterson, Cora, Grosse, Scott D., Glidewell, Jill, Garg, Lorraine F., Van Naarden Braun, Kim, Knapp, Mary M., Beres, Leslie M., Hinton, Cynthia F., Olney, Richard S., and Cassell, Cynthia H.
- Abstract
Objective. Critical congenital heart disease (CCHD) was recently added to the U.S. Recommended Uniform Screening Panel for newborns. This evaluation aimed to estimate screening time and hospital cost per newborn screened for CCHD using pulse oximetry as part of a public health economic assessment of CCHD screening. Methods. A cost survey and time and motion study were conducted in well-newborn and special/intensive care nurseries in a random sample of seven birthing hospitals in New Jersey, where the state legislature mandated CCHD screening in 2011. The sample was stratified by hospital facility level, hospital birth census, and geographic location. At the time of the evaluation, all hospitals had conducted CCHD screening for at least four months. Results. Mean screening time per newborn was 9.1 (standard deviation 5 3.4) minutes. Hospitals' total mean estimated cost per newborn screened was $14.19 (in 2011 U.S. dollars), consisting of $7.36 in labor costs and $6.83 in equipment and supply costs. Conclusions. This federal agency-state health department collaborative assessment is the first state-level analysis of time and hospital costs for CCHD screening using pulse oximetry conducted in the U.S. Hospitals' cost per newborn screened for CCHD with pulse oximetry is comparable with cost estimates of existing newborn screening tests. Hospitals' equipment costs varied substantially based on the pulse oximetry technology employed, with lower costs among hospitals that used reusable screening sensors. In combination with estimates of screening accuracy, effectiveness, and avoided costs, information from this evaluation suggests that CCHD screening is cost-effective. [ABSTRACT FROM AUTHOR]
- Published
- 2014
22. A Public Health Economic Assessment of Hospitals' Cost to Screen Newborns for Critical Congenital Heart Disease.
- Author
-
PETERSON, CORA, GROSSE, SCOTT D., GLIDEWELL, JILL, GARG, LORRAINE F., VAN NAARDEN BRAUN, KIM, KNAPP, MARY M., BERES, LESLIE M., HINTON, CYNTHIA F., OLNEY, RICHARD S., and CASSELL, CYNTHIA H.
- Subjects
- *
CONGENITAL heart disease , *MEDICAL cooperation , *MEDICAL screening , *NEONATAL intensive care , *OXIMETRY , *POPULATION geography , *RESEARCH , *STATISTICAL sampling , *WORK measurement , *COST analysis , *NEONATAL intensive care units , *EQUIPMENT & supplies , *DISEASE risk factors - Abstract
Objective. Critical congenital heart disease (CCHD) was recently added to the U.S. Recommended Uniform Screening Panel for newborns. This evaluation aimed to estimate screening time and hospital cost per newborn screened for CCHD using pulse oximetry as part of a public health economic assessment of CCHD screening. Methods. A cost survey and time and motion study were conducted in well-newborn and special/intensive care nurseries in a random sample of seven birthing hospitals in New Jersey, where the state legislature mandated CCHD screening in 2011. The sample was stratified by hospital facility level, hospital birth census, and geographic location. At the time of the evaluation, all hospitals had conducted CCHD screening for at least four months. Results. Mean screening time per newborn was 9.1 (standard deviation 5 3.4) minutes. Hospitals' total mean estimated cost per newborn screened was $14.19 (in 2011 U.S. dollars), consisting of $7.36 in labor costs and $6.83 in equipment and supply costs. Conclusions. This federal agency-state health department collaborative assessment is the first state-level analysis of time and hospital costs for CCHD screening using pulse oximetry conducted in the U.S. Hospitals' cost per newborn screened for CCHD with pulse oximetry is comparable with cost estimates of existing newborn screening tests. Hospitals' equipment costs varied substantially based on the pulse oximetry technology employed, with lower costs among hospitals that used reusable screening sensors. In combination with estimates of screening accuracy, effectiveness, and avoided costs, information from this evaluation suggests that CCHD screening is cost-effective. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
23. Actions in Support of Newborn Screening for Critical Congenital Heart Disease -- United States, 2011-2018.
- Author
-
Glidewell, Jill, Grosse, Scott D., Riehle-Colarusso, Tiffany, Pinto, Nelangi, Hudson, Jeff, Daskalov, Rachel, Gaviglio, Amy, Darby, Erin, Singh, Sikha, and Sontag, Marci
- Subjects
- *
CONGENITAL heart disease diagnosis , *DISEASE risk factors , *NEWBORN screening , *HYPOXEMIA , *CATASTROPHIC illness , *INTERPROFESSIONAL relations , *CONGENITAL heart disease , *HEALTH outcome assessment , *OXIMETRY , *POLICY sciences , *PUBLIC health surveillance , *QUALITY assurance , *PULSE oximeters , *DISEASE management , *HUMAN services programs , *EARLY diagnosis , *PROGNOSIS , *DIAGNOSIS , *MEDICAL laws , *THERAPEUTICS ,MORTALITY risk factors - Abstract
The article deals with the decision of the U.S. Department of Health and Human Services in 2001 to add critical congenital heart disease (CCHD) to the list of conditions recommended to states for universal newborn screening. Topics covered include a decline in mortality from CCHD and other cardiac causes in infants less than six months based on 2007-2013 data. A table is also presented that shows state legislation and regulations for newborn screening for CCHD from 2011 to 2018.
- Published
- 2019
24. Correlates of In-Hospital Deaths among Hospitalizations with Pulmonary Embolism: Findings from the 2001-2008 National Hospital Discharge Survey.
- Author
-
Tsai, James, Grosse, Scott D., Grant, Althea M., Reyes, Nimia L., Hooper, W. Craig, and Atrash, Hani K.
- Subjects
- *
MORTALITY , *PULMONARY embolism , *HOSPITAL care , *QUALITY of life , *HOSPITAL admission & discharge , *REGRESSION analysis - Abstract
Background: Deep vein thrombosis and pulmonary embolism (PE) are responsible for substantial mortality, morbidity, and impaired health-related quality of life. The aim of this study was to evaluate the correlates of in-hospital deaths among hospitalizations with a diagnosis of PE in the United States. Methods: By using data from the 2001-2008 National Hospital Discharge Survey, we assessed the correlates of in-hospital deaths among 14,721 hospitalizations with a diagnosis of PE and among subgroups stratified by age, sex, race, days of hospital stay, type of admission, cancer, pneumonia, and fractures. We produced adjusted rate ratios (aRR) and 95% confidence intervals using log-linear multivariate regression models. Results: Regardless of the listing position of diagnostic codes, we observed an increased likelihood of in-hospital death in subgroups of hospitalizations with ages 50 years and older (aRR = 1.82-8.48), less than 7 days of hospital stay (aRR = 1.43-1.57), cancer (aRR = 2.10-2.28), pneumonia (aRR = 1.79-2.20), or fractures (aRR = 2.18) (except for first-listed PE), when compared to the reference groups with ages 1-49 years, 7 days or more of hospital stay, without cancer, pneumonia, or fractures while adjusting for covariates. In addition, we observed an increased likelihood of in-hospital death for first-listed PE in hospitalizations of women, when compared to those of men (aRR = 1.45). Conclusions: The results of this study provide support for identifying, developing, and implementing effective, evidencebased clinical assessment and management strategies to reduce PE-related morbidity and mortality among hospitalized PE patients who may have concurrent health conditions including cancer, pneumonia, and fractures. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
25. A National Profile of Health Care and Family Impacts of Children With Muscular Dystrophy and Special Health Care Needs in the United States.
- Author
-
Ouyang, Lijing, Grosse, Scott D., Fox, Michael H., and Bolen, Julie
- Subjects
- *
MEDICAL needs assessment , *MUSCULAR dystrophy in children , *HEALTH outcome assessment , *SOCIODEMOGRAPHIC factors , *HEALTH self-care - Abstract
We used the 2005−2006 National Survey of Children with Special Health Care Needs to compare 3 types of outcomes between children with and those without parental reported muscular dystrophy: (1) functional limitations; (2) health care experiences in terms of the 5 components of a medical home; and (3) family impacts, including financial or out-of-pocket costs and parental employment and time use. We used weighted logistic regression to examine their associations with muscular dystrophy after adjustment for socio-demographic characteristics. Among children with special health care needs, children with reported muscular dystrophy were much more likely to have difficulties with ambulation and self-care. They were more likely to have family members who reported financial problems, reduced or stopped employment, and spent more than 10 hours weekly providing or coordinating care. Muscular dystrophy was not associated with the likelihood of having a medical home after adjustment for socioeconomic status and other socio-demographic characteristics. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
26. Health Utility Elicitation Is There Still a Role for Direct Methods?
- Author
-
Prosser, Lisa A., Grosse, Scott D., and Wittenberg, Eve
- Subjects
- *
METHODOLOGY , *MEDICAL care , *PUBLIC health , *HUMAN services - Abstract
The article reflects on the role of direct method in health utility elicitation. It is said that the important advantages of indirect methods in ease of use and comparability of results across studies may be tempered by their limited descriptive ability to capture all health attributes of a condition. It is also said that the indirect measures exclude the altruistic component of spillover effects.
- Published
- 2012
- Full Text
- View/download PDF
27. Prevalence of Congenital Hypothyroidism—Current Trends and Future Directions: Workshop Summary.
- Author
-
Olney, Richard S., Grosse, Scott D., and Vogt Jr., Robert F.
- Subjects
- *
CONFERENCES & conventions , *NEONATAL diseases , *CONGENITAL hypothyroidism , *ETIOLOGY of diseases - Abstract
In response to published newborn-screening data that have shown an increase in the incidence (birth prevalence) rate of primary congenital hypothyroidism (CH) in the United States, a workshop was held in Atlanta, Georgia, on February 27 and 28, 2008, to examine this issue. Topics of the meeting included pathophysiology, medical management, and follow-up of CH; transient hypothyroidism (etiology, clinical implications, management, and changes in prevalence); risk factors for CH; laboratory approaches to newborn screening for CH; state-specific evaluations of trends in incidence rates of CH; and concluding discussions on future directions to resolve outstanding issues. Through presentations and discussion, gaps in knowledge were identified, such as the lack of consistent definitions for CH and transient hypothyroidism and the effects of preventable risk factors on incidence rates of CH. One outcome of the meeting was a series of accompanying articles that examined (1) trends in the incidence rates of CH in individual states and nationally, (2) effects of newborn-screening practices on CH-incidence rates, (3) the contribution of transient hypothyroidism to CH-incidence rates, and (4) future research directions. In this summary, we briefly touch on the topics of these articles and examine highlights of other presentations from the workshop that illuminated the secular trends in reported CH-incidence rates in the United States. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
28. Late-Treated Phenylketonuria and Partial Reversibility of Intellectual Impairment.
- Author
-
Grosse, Scott D.
- Subjects
- *
AMINO acid metabolism disorders , *PHENYLKETONURIA treatment , *INTELLIGENCE levels , *CHILD development , *INTELLECTUAL development , *COGNITIVE ability , *THERAPEUTICS , *NUTRITION - Abstract
Individuals with late-treated phenylketonuria (PKU) not detected by newborn screening but who followed dietary treatment for at least 12 months before 7 years of age have intelligence quotient (IQ) scores that range from severe impairment to the low-normal range. Among adults with late-treated PKU in California, 85% of those who were born from 1961 to 1978 had IQ scores of 70 or above. Longitudinal studies with repeated cognitive assessments often show average changes in cognitive test scores as high as 20-45 points. Although the severe cognitive impairment associated with untreated PKU can in many cases be partially reversed with dietary treatment, prompt initiation of treatment following newborn metabolic screening is essential for optimal development and the prevention of disability. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
29. Challenges of translating genetic tests into clinical and public health practice.
- Author
-
Rogowski, Wolf H., Grosse, Scott D., and Khoury, Muin J.
- Subjects
- *
GENETIC translation , *GENETIC polymorphisms , *GENOTYPE-environment interaction , *MEDICAL care , *HUMAN services - Abstract
Research in genetics and genomics has led to an expanding list of molecular genetic tests, which are increasingly entering health care systems. However, the evidence surrounding the benefits and harms of these tests is frequently weak. Here we present the main challenges to the successful translation of new research findings about genotype-phenotype associations into clinical practice. We discuss the means to achieve an accelerated translation research agenda that is conducted in a reasonable, fair and efficient manner. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
30. Children with Orofacial Clefts: Health-Care Use and Costs Among a Privately Insured Population.
- Author
-
Boulet, Sheree L., Grosse, Scott D., Honein, Margaret A., and Correa-Villaseñor, Adolfo
- Subjects
- *
CLEFT palate , *MEDICAL care costs , *HUMAN abnormalities , *CHILD health services , *PUBLIC health , *ACCOUNTING ,HEALTH insurance finance - Abstract
Objectives. Orofacial clefts are common birth defects that often require multiple surgeries and medical treatments during childhood. We used health-care insurance claims data to estimate health-care expenditures for infants and children ⩽10 years of age with an orofacial cleft. Methods. The data were derived from the 2000-2004 MarketScan® Commercial Claims and Encounters databases, which include person-specific information on health-care use, expenditures, and enrollment for approximately 50 large employers, health plans, and government and public organizations. Health insurance claims data from 821,619 children ⩽10 years of age enrolled in employer-sponsored plans during 2004 were analyzed. Expenditures for inpatient admissions, outpatient services, and prescription drug claims were calculated for children with and those without an orofacial cleft. Results. The difference in annual mean costs (i.e., incremental costs) between children aged 0 through 10 years with an orofacial cleft and those without an orofacial cleft was $13,405. The mean and median costs for children ⩽10 years of age with an orofacial cleft were eight times higher than for children of the same age without an orofacial cleft. Mean costs for infants with a cleft and another major, unrelated defect were 25 times higher than those for an infant without a cleft, and five times higher than for infants with an isolated cleft. Conclusion. These findings document substantially elevated medical care costs for privately insured children with an orofacial cleft. Additional study of the economic burden associated with this condition should include a broader range of economic costs. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
31. Disability and Disability-Adjusted Life Years: Not the Same.
- Author
-
Grosse, Scott D., Lollar, Donald J., Campbell, Vincent A., and Chamie, Mary
- Subjects
- *
PUBLIC health , *HUMAN services personnel , *HEALTH , *DISABILITIES , *HUMAN services - Abstract
The article discusses the need for public health professionals to understand the relation of disability-adjusted life year (DALY) to contemporary understanding of compatibility. It relates that the widespread use of DALY is due to the fact that it provides a means of comparing health impact to a varied range of medical conditions. It states that another clarification related to the issue asserts that DALY is based only on experts' perception and not on the reported experience of disabled people.
- Published
- 2009
- Full Text
- View/download PDF
32. Models of Comprehensive Multidisciplinary Care for Individuals in the United States With Genetic Disorders.
- Author
-
Grosse, Scott D., Schechter, Michael S., Kulkarni, Roshni, Lloyd-Puryear, Michele A., Strickland, Bonnie, and Trevathan, Edwin
- Subjects
- *
GENETIC disorders , *PATIENTS , *HOME care services , *PRIMARY care , *HEALTH services administration - Abstract
Approaches to providing comprehensive coordinated care for individuals with complex diseases include the medical home approach, the chronic care model in primary care, and disease-specific, multidisciplinary specialty clinics. There is uneven availability and utilization of multidisciplinary specialty clinics for different genetic diseases. For 2 disorders (ie, hemophilia and cystic fibrosis), effective national networks of specialty clinics exist and reach large proportions of the target populations. For other disorders, notably, sickle cell disease, fewer such centers are available, centers are less likely to be networked, and centers are used less widely. Models of comanagement are essential for promoting ongoing communication and coordination between primary care and subspecialty services, particularly during the transition from pediatric care to adult care. Evaluation of the effectiveness of different models in improving outcomes for individuals with genetic diseases is essential. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
33. Economic Evaluation of a Neural Tube Defect Recurrence–Prevention Program
- Author
-
Grosse, Scott D., Ouyang, Lijing, Collins, Julianne S., Green, Denise, Dean, Jane H., and Stevenson, Roger E.
- Subjects
- *
COST effectiveness , *NEURAL tube defects , *FETAL death , *SPINE abnormalities - Abstract
Background: Women with a pregnancy affected by a neural tube defect (NTD) are encouraged to take folic acid prior to a subsequent pregnancy, but it is unknown whether organized attempts to identify and counsel such women to prevent recurrent NTDs are cost effective. Methods: Data from the South Carolina recurrence–prevention program for October 2001–September 2002 were analyzed between October 2002 and December 2003 to calculate costs. Cost-effectiveness modeling of the program during 1992–2006 was conducted during 2007. Results were calculated for three scenarios based on recurrence risk, supplement use, and the effectiveness of folic acid in preventing recurrences. For each scenario, quality-adjusted life years (QALYs) were calculated separately using prevented NTD-affected live births; prevented NTD-affected births (including fetal deaths); and all prevented NTD-affected pregnancies. Results: The prevention program cost approximately $155,000 per year in 2003 dollars to protect 35 pregnancies and prevent approximately one NTD. The direct costs associated with an NTD depend on type and outcome, but are approximately $560,000 in 2003 dollars for a live birth with spina bifida. The base-case cost-effectiveness ratio was $39,600 per QALY gained from avoided NTD-affected live births and stillbirths, and $14,700 per QALY gained from the avoidance of all NTD-affected pregnancies. The baseline NTD recurrence risk and the use of folic acid supplements by women who are at high risk for an NTD-affected pregnancy were influential parameters. Conclusions: The South Carolina NTD recurrence–prevention program appears comparable in cost effectiveness to other preventive services. Other states might consider including NTD recurrence prevention in birth defect–prevention programs. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
34. Health state preference scores for children with permanent childhood hearing loss: a comparative analysis of the QWB and HUI3.
- Author
-
Smith-Olinde, Laura, Grosse, Scott D., Olinde, Frank, Martin, Patti F., and Tilford, John M.
- Subjects
- *
DEAFNESS in children , *HEARING disorders in children , *QUALITY of life , *COCHLEAR implants , *HEARING impaired , *AUDIOLOGY , *THERAPEUTICS - Abstract
The aim of this study was to compare two preference-weighted, caregiver-reported measures of health-related quality of life for children with permanent childhood hearing loss to determine whether cost-effectiveness analysis applied to deaf and hard of hearing populations will provide similar answers based on the choice of instrument. Caregivers of 103 children in Arkansas, USA, with documented hearing loss completed the Quality of Well-Being Scale (QWB) and the Health Utilities Index Mark 3 (HUI3) to describe the health status of their children. Audiology and other clinical measures were abstracted from medical records. Mean scores were compared overall and by degree of hearing loss. Linear regression was used to correlate preference scores with a four-frequency pure-tone average, cochlear implant status, and other factors. Mean preference scores for the QWB and HUI3 were similar (0.601 and 0.619, respectively) although the HUI3 demonstrated a wider range of values (−0.132 to 1.000) compared to the QWB (0.345–0.854) and was more sensitive to mild hearing loss. Both measures correlated with the pure-tone average, were negatively associated with comorbid conditions and positively associated with cochlear implant status. In the best fitting regression models, similar estimates for cochlear implant status and comorbid conditions were obtained from the two measures. Despite considerable differences in the HUI3 and the QWB scale, we found agreement between the two instruments at the mean, but clinically important differences across a number of measures. The two instruments are likely to yield different estimates of cost-effectiveness ratios, especially for interventions involving mild to moderate hearing loss. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
35. Health Care Utilization and Expenditures for Children and Young Adults With Muscular Dystrophy in a Privately Insured Population.
- Author
-
Ouyang, Lijing, Grosse, Scott D., and Kenneson, Aileen
- Subjects
- *
MEDICAL care use , *MEDICAL care costs , *MUSCULAR dystrophy , *NEUROMUSCULAR diseases , *YOUNG adults - Abstract
We provide estimates of medical care utilization and expenditures for children and young adults younger than age 30 with muscular dystrophies in the United States. Accurate estimates are essential for calculations of lifetime costs and for economic evaluations of screening and management strategies for muscular dystrophy. We compare the medical expenditures for persons with muscular dystrophy with others by age groups. The incremental annual expenditures of medical care for privately insured individuals with muscular dystrophy relative to others in 2004 averaged $18 930 and ranged from $13 464 at ages 5 to 9 to $32 541 at ages 15 to 19. Individuals with muscular dystrophy had average medical expenditures 10 to 20 times greater than individuals without muscular dystrophy. Individuals aged 15 to 19 years had the highest number of inpatient admissions related to respiratory infections and cardiac complications. The findings underscore the need for appropriate treatment options for individuals with muscular dystrophy as they age. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
36. Medical Expenditures for Children with an Autism Spectrum Disorder in a Privately Insured Population.
- Author
-
Shimabukuro, Tom T., Grosse, Scott D., and Rice, Catherine
- Subjects
- *
DIAGNOSIS of autism in children , *AUTISM in adolescence , *MEDICAL care costs , *EMPLOYER-sponsored health insurance , *DATABASES , *DEVELOPMENTAL disabilities - Abstract
This study provides estimates of medical expenditures for a subset of children and adolescents who receive employer-based health insurance and have a medical diagnosis of an autism spectrum disorder (ASD). Data analyzed were from the 2003 MarketScan® research databases. Individuals with an ASD had average medical expenditures that exceeded those without an ASD by $4,110–$6,200 per year. On average, medical expenditures for individuals with an ASD were 4.1–6.2 times greater than for those without an ASD. Differences in median expenditures ranged from $2,240 to $3,360 per year with median expenditures 8.4–9.5 times greater. These findings add to a growing body of evidence that children and adolescents with medical diagnoses of an ASD incur elevated medical utilization and costs. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
37. Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: A quantitative assessment
- Author
-
Grosse, Scott D., Ross, Danielle S., and Dollard, Sheila C.
- Subjects
- *
CYTOMEGALOVIRUS diseases , *GENETIC disorders , *HEARING disorders , *EXOCRINE secretions , *SALIVA - Abstract
Abstract: Background: Congenital cytomegalovirus (CMV) infection is a cause of sensorineural hearing loss (SNHL) in children, but the magnitude of its contribution is uncertain. Quantifying the impact of congenital CMV infection requires an evidence-based assessment using a standard case definition of hearing loss. Objectives: To determine the frequency of bilateral moderate to profound SNHL in children with congenital CMV infection and to estimate the CMV-attributable fraction of bilateral moderate to profound SNHL. Study design: A systematic review of studies of children with congenital CMV infection ascertained in an unbiased manner through universal newborn screening for CMV using viral culture in urine or saliva specimens in combination with a review of the literature on congenital CMV infection and hearing loss, including articles of all types. Results: Approximately, 14% of children with congenital CMV infection develop SNHL of some type, and 3–5% develop bilateral moderate to profound SNHL. Among all children with bilateral moderate to profound SNHL, we estimate that 15–20% of cases are attributable to congenital CMV infection. Conclusions: Congenital CMV infection is one of the most important causes of hearing loss in young children, second only to genetic mutations, and is potentially preventable. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
38. Issues related to the diagnosis and treatment of autism spectrum disorders.
- Author
-
Shattuck, Paul T. and Grosse, Scott D.
- Subjects
- *
TREATMENT of autism , *DIAGNOSIS , *SPECIAL education , *DEVELOPMENTAL disabilities , *HEALTH policy - Abstract
This paper explores issues and implications for diagnosis and treatment, stemming from the growing number of children identified with autism spectrum disorders (ASDs). Recent developments and innovations in special education and Medicaid programs are emphasized. Eligibility determination policies, innovations in diagnostic practices, the cost and financing of assessment, variability among programs in diagnostic criteria, and racial/ethnic disparities in the timing of diagnosis all influence the capacity of service systems to provide diagnoses in a timely, coordinated, accurate, economical, and equitable manner. There are several barriers to the more widespread provision of intensive intervention for children with ASDs, including lack of strong evidence of effectiveness in scaled-up public programs, uncertainty about the extent of obligations to provide services under the Individuals with Disabilities Education Act, high cost of intervention, and variability among states in their willingness to fund intensive intervention via Medicaid. Innovative policy experiments with respect to financing intensive intervention through schools and Medicaid are being conducted in a number of states. © 2007 Wiley-Liss, Inc. MRDD Research Reviews 2007;13:129–135. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
39. How Many Deaths Can Be Prevented by Newborn Screening for Congenital Adrenal Hyperplasia?
- Author
-
Grosse, Scott D. and Van Vliet, Guy
- Subjects
- *
ADRENOGENITAL syndrome , *MEDICAL screening , *MORTALITY , *ADRENAL diseases , *HEALTH risk assessment - Abstract
Background/Aims: Congenital adrenal hyperplasia (CAH) is increasingly being included in newborn screening programs. Screening can prevent neonatal mortality in children with salt-wasting CAH, but the number of deaths prevented is not known. Cost-effectiveness analyses of screening require estimates of the probability of mortality in CAH. Methods: We reviewed the literature to identify cohort studies of children with CAH ascertained clinically in the absence of screening. We abstracted the numbers of infant deaths attributable to CAH. We also addressed sex ratios among children with clinically detected CAH and the contribution of ascertainment bias to unbalanced ratios. Results: The evidence suggests a probability of infant death due to adrenal crises in salt-wasting CAH of 4% or less in contemporary advanced economies without screening for CAH. This is lower than previous estimates, although the rate of mortality could be considerably higher in populations with limited clinical awareness or access. Conclusion: Although screening for CAH is conducted in a number of countries, further research is still needed to provide reliable estimates on the numbers of prevented deaths, along with evidence-based assessments of the potential benefits, harms, and costs of screening. Copyright © 2007 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
40. Lessons from Cost-Effectiveness Research for United States Public Health Policy.
- Author
-
Grosse, Scott D., Teutsch, Steven M., and Haddix, Anne C.
- Subjects
- *
PUBLIC health , *HEALTH policy , *COST effectiveness , *MEDICAL care , *HEALTH promotion - Abstract
The application of cost-effectiveness analysis to health care has been the subject of previous reviews. We address the use of economic evaluation methods in public health, including case studies of population-level policies, e.g., environmental regulations, injury prevention, tobacco control, folic acid fortification, and blood product safety, and the public health promotion of clinical preventive services, e.g., newborn screening, cancer screening, and childhood immunizations. We review the methods used in cost-effectiveness analysis, the implications for cost-effectiveness findings, and the extent to which economic studies have influenced policy and program decisions. We discuss reasons for the relatively limited impact to date of economic evaluation in public health. Finally, we address the vexing question of how to decide which interventions are cost effective and worthy of funding. Policy makers have funded certain interventions with rather high cost-effectiveness ratios, notably nucleic acid testing for blood product safety. Cost-effectiveness estimates are a decision aid, not a decision rule. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
41. The Business Case for Preconception Care: Methods and Issues.
- Author
-
Grosse, Scott D., Sotnikov, Sergey V., Leatherman, Sheila, and Curtis, Michele
- Subjects
- *
PRECONCEPTION care , *GESTATIONAL diabetes , *HUMAN abnormalities , *PREGNANCY complications , *MATERNAL health services , *PRENATAL care - Abstract
Only a limited number of economic evaluations have addressed the costs and benefits of preconception care. In order to persuade health care providers, payers, or purchasers to become actively involved in promoting preconception care, it is important to demonstrate the value of doing so through development of a “business case”. Perceived benefits in terms of organizational reputation and market share can be influential in forming a business case. In addition, it is standard to include an economic analysis of financial costs and benefits from the perspective of the provider practice, payer, or purchaser in a business case. The methods, data needs, and other issues involved with preparing an economic analysis of the likely financial return on investment in preconception care are presented here. This is accompanied by a review or case study of economic evaluations of preconception care for women with recognized diabetes. Although the data are not sufficient to draw firm conclusions, there are indications that such care may yield positive financial benefits to health care organizations through reduction in maternal and infant hospitalizations. More work is needed to establish how costs and economic benefits are distributed among different types of organizations. Also, the optimum methods of delivering preconception care for women with diabetes need to be evaluated. Similar assessments should also be conducted for other forms of preconception care, including comprehensive care. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
42. From Public Health Emergency to Public Health Service: The Implications of Evolving Criteria for Newborn Screening Panels.
- Author
-
Grosse, Scott D., Boyle, Coleen A., Kenneson, Aileen, Khoury, Muin J., and Wilfond, Benjamin S.
- Subjects
- *
MEDICAL screening , *DISEASES , *NEWBORN infants , *EVIDENCE-based pediatrics , *PUBLIC health , *NEONATOLOGY - Abstract
Argues that the selection of disorders for population-based newborn screening should follow the standards of evidence-based public health. Opinion on a report from the American College of Medical Genetics; History of newborn screening; Changes in the criteria for newborn screening; Challenges associated with the efforts to expand screening panels.
- Published
- 2006
- Full Text
- View/download PDF
43. Reevaluating the Benefits of Folic Acid Fortification in the United States: Economic Analysis, Regulation, and Public Health.
- Author
-
Grosse, Scott D., Mulinare, Joseph, Waitzman, Norman J., and Romano, Patrick S.
- Subjects
- *
FOLIC acid , *PREPARED cereals , *CEREAL products , *NEURAL tube defects , *HUMAN abnormalities , *PREVENTION - Abstract
Before a 1996 US regulation requiring fortification of enriched cereal-grain products with folic acid, 3 economic evaluations projected net economic benefits or cost savings of folic acid fortification resulting from the prevention of pregnancies affected by a neural tube defect. Because the observed decline in neural tube defect rates is greater than was forecast before fortification, the economic gains are correspondingly larger. Applying both cost-benefit and cost-effectiveness analytic techniques, we estimated that folic acid fortification is associated with annual economic benefit of $312 million to $425 million. The cost savings (net reduction in direct costs) were estimated to be in the range of $88 million to $145 million per year. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
44. Health state preference scores of children with spina bifida and their caregivers.
- Author
-
Tilford, John M., Grosse, Scott D., Robbins, James M., Pyne, Jeffrey M., Cleves, Mario A., and Hobbs, Charlotte A.
- Subjects
- *
COST effectiveness , *CHILD care , *MEDICAL care , *PRIMARY care , *MULTIVARIATE analysis , *THERAPEUTICS , *FAMILIES & psychology , *PSYCHOLOGY of caregivers , *COMPARATIVE studies , *HEALTH status indicators , *RESEARCH methodology , *MEDICAL cooperation , *PATIENT satisfaction , *PSYCHOLOGY of children with disabilities , *QUALITY of life , *RESEARCH , *RESEARCH funding , *EVALUATION research , *QUALITY-adjusted life years , *SPINA bifida , *DISEASE progression , *PREVENTION - Abstract
Cost-effectiveness evaluations of interventions to prevent or treat spina bifida require quality of life information measured as preference scores. Preference scores of caregivers also may be relevant. This study tested whether the preference scores of children with spina bifida and their caregivers would decrease as disability in the child increased. Families of children aged 0-17 with spina bifida (N = 98) were identified using a birth defect surveillance system in the state of Arkansas. Primary caregivers of children with spina bifida identified other families with an unaffected child (N = 49). Preference scores for child health states were determined using the Health Utilities Index--Mark 2 (HUI2). Caregiver preference scores were determined using the Quality of Well-Being (QWB) scale. Children with spina bifida were categorized into three disability levels according to the location of the child's lesion. Mean preference scores declined for both affected children and the primary caregiver as disability in the child increased. In multivariate analysis, the preference score of the child was a significant and positive predictor of the primary caregiver's preference score. A more modest association was found for caregiver health preference scores by lesion location. The findings can inform cost-effectiveness evaluations of interventions to treat or prevent spina bifida. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
45. Autism Spectrum Disorder Diagnoses and Congenital Cytomegalovirus.
- Author
-
Pesch, Megan H., Leung, Jessica, Lanzieri, Tatiana M., Tinker, Sarah C., Rose, Charles E., Danielson, Melissa L., Yeargin-Allsopp, Marshalyn, and Grosse, Scott D.
- Subjects
- *
DIAGNOSIS of autism , *STATISTICAL correlation , *HUMAN abnormalities , *HEALTH insurance reimbursement , *RESEARCH funding , *CYTOMEGALOVIRUS diseases , *HEALTH insurance , *SEX distribution , *EVALUATION of medical care , *CENTRAL nervous system , *DESCRIPTIVE statistics , *DISEASE prevalence , *LONGITUDINAL method , *SURVEYS , *RESEARCH , *CONFIDENCE intervals , *COMPARATIVE studies , *MEDICAID , *PROPORTIONAL hazards models , *REGRESSION analysis , *CHILDREN - Abstract
OBJECTIVE: To examine the association between congenital cytomegalovirus (cCMV) and autism spectrum disorder (ASD) administrative diagnoses in US children. METHODS: Cohort study using 2014 to 2020 Medicaid claims data.We used diagnosis codes to identify cCMV (exposure), ASD (outcome), and covariates among children enrolled from birth through ≥4 to <7 years. Covariates include central nervous system (CNS) anomaly or injury diagnosis codes, including brain anomaly, microcephaly within 45 days of birth, cerebral palsy, epilepsy, or chorioretinitis. We used Cox proportional hazards regression models to estimate hazard ratios and 95% confidence intervals, overall and stratified by sex, birth weight and gestational age outcome (low birth weight or preterm birth), and presence of CNS anomaly or injury. RESULTS: Among 2 989 659 children, we identified 1044 (3.5 per 10 000) children with cCMV and 74 872 (25.0 per 1000) children with ASD. Of those with cCMV, 49% also had CNS anomaly or injury diagnosis codes. Children with cCMV were more likely to have ASD diagnoses (hazard ratio: 2.5; 95% confidence interval: 2.0-3.2, adjusting for birth year, sex, and region). This association differed by sex and absence of CNS anomaly or injury but not birth outcome. CONCLUSIONS: Children with (versus without) cCMV diagnoses in Medicaid claims data, most of whom likely had symptomatic cCMV, were more likely to have ASD diagnoses. Future research investigating ASD risk among cohorts identified through universal cCMV screening may help elucidate these observed associations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. THE POLITICS OF FAMILY PLANNING IN THE MAGHRIB.
- Author
-
Grosse, Scott D.
- Subjects
- *
BIRTH control , *POLITICAL science - Abstract
Discusses the politics of family planning in the Maghrib states of Morocco, Algeria and Tunisia. Approaches to the political context of family planning; Description of a family planning program; Chronology of family planning in the three states.
- Published
- 1982
- Full Text
- View/download PDF
47. Considering Antiviral Treatment to Preserve Hearing in Congenital CMV.
- Author
-
Lanzieri, Tatiana M., Pesch, Megan H., and Grosse, Scott D.
- Subjects
- *
DEAFNESS prevention , *HEARING , *GANCICLOVIR , *CYTOMEGALOVIRUS diseases , *ANTIVIRAL agents , *PUBLIC health , *DEVELOPMENTAL disabilities , *DECISION making - Abstract
The authors comment on antiviral treatment to preserve hearing in congenital cytomegalovirus (cCMV), the leading nongenetic cause of sensorineural hearing loss (SNHL) in children. Topics discussed include reason newborns are usually tested for cCMV, clinical trials about ganciclovir or valganciclovir conducted by the Collaborative Antiviral Study Group (CASG) and lack of evidence of the efficacy of antiviral medication on hearing preservation in infants with asymptomatic cCMV.
- Published
- 2023
- Full Text
- View/download PDF
48. Medical expenditures of children in the United States with fetal alcohol syndrome
- Author
-
Amendah, Djesika D., Grosse, Scott D., and Bertrand, Jacquelyn
- Subjects
- *
MEDICAL care costs , *COGNITION disorders in children , *PEDIATRICS , *FETAL alcohol syndrome , *MEDICAL centers , *PRENATAL influences , *MEDICAID , *NOSOLOGY - Abstract
Abstract: This paper calculates the medical expenditures for pediatric Medicaid enrollees with fetal alcohol syndrome (FAS), those with and those without reported intellectual disability (ID). The pediatric portion of the MarketScan® Medicaid Multi-State databases for the years 2003–2005 was used. Children with FAS were identified based on International Classification of Diseases, Ninth Revision, Clinical Modification codes. Children without FAS formed the comparison group. Annual mean, median, and 95th percentile total expenditures were calculated for those continuously enrolled during 2005. Children with FAS incurred annual mean medical expenditures that were nine times as high as those of children without FAS during 2005 ($16,782 vs. $1,859). ID more commonly was listed as a medical diagnosis among children with FAS than among children in the comparison group (12% vs. 0.5%), and mean expenditures of children with FAS and ID were 2.8 times those of children with FAS but without reported ID. Children with FAS incurred higher medical expenditures compared with children without FAS. A subset of children with FAS who had ID sufficiently serious to be recorded in medical records increased those expenditures still further. Our estimate of mean expenditures for children with FAS was several times higher than previous estimates in the United States. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
49. Estimation of Coronavirus Disease 2019 Hospitalization Costs From a Large Electronic Administrative Discharge Database, March 2020–July 2021.
- Author
-
Shrestha, Sundar S, Kompaniyets, Lyudmyla, Grosse, Scott D, Harris, Aaron M, Baggs, James, Sircar, Kanta, and Gundlapalli, Adi V
- Abstract
Background Information on the costs of inpatient care for patients with coronavirus disease 2019 (COVID-19) is very limited. This study estimates the per-patient cost of inpatient care for adult COVID-19 patients seen at >800 US hospitals. Methods Patients aged ≥18 years with ≥1 hospitalization during March 2020–July 2021 with a COVID-19 diagnosis code in a large electronic administrative discharge database were included. We used validated costs when reported; otherwise, costs were calculated using charges multiplied by cost-to-charge ratios. We estimated costs of inpatient care per patient overall and by severity indicator, age, sex, underlying medical conditions, and acute complications of COVID-19 using a generalized linear model with log link function and gamma distribution. Results The overall cost among 654673 patients hospitalized with COVID-19 was $16.2 billion. Estimated per-patient hospitalization cost was $24 826. Among surviving patients, estimated per-patient cost was $13 090 without intensive care unit (ICU) admission or invasive mechanical ventilation (IMV), $21 222 with ICU admission alone, and $59 742 with IMV. Estimated per-patient cost among patients who died was $27 017. Adjusted cost differential was higher among patients with certain underlying conditions (eg, chronic kidney disease [$12 391], liver disease [$8878], cerebrovascular disease [$7267], and obesity [$5933]) and acute complications (eg, acute respiratory distress syndrome [$43 912], pneumothorax [$25 240], and intracranial hemorrhage [$22 280]). Conclusions The cost of inpatient care for COVID-19 patients was substantial through the first 17 months of the pandemic. These estimates can be used to inform policy makers and planners and cost-effectiveness analysis of public health interventions to alleviate the burden of COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
50. Cost-of-illness models for venous thromboembolism: One size does not fit all.
- Author
-
Grosse, Scott D.
- Subjects
- *
VENOUS thrombosis prevention , *MEDICAL care costs , *MEDICAL economics , *MEDICAL research , *COHORT analysis - Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.